FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to therapy, cardiology, pulmonology, endocrinology, and can be used for individual prediction of a risk of post-covid syndrome (PCS) in males. Patient is examined for age, LAP and HOMA indices, arterial hypertension (AH), left ventricular diastolic dysfunction (LVDD). Obtained data are assessed using a point scale, obtained points are summed up. If the total score is < 7 points, a low risk is stated, and if the total score ≥ 7 points indicates a high risk of developing PCS in males.
EFFECT: method enables the well-timed detection of the patients with a high risk of developing PCS, the selection of a therapeutic approach and the early prevention of complications of the coronavirus infection by assessing a set of the most significant indicators.
1 cl, 1 dwg, 8 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTION OF RISK OF DEVELOPING ARTERIAL HYPERTENSION AFTER COVID-19 PNEUMONIA | 2024 |
|
RU2828988C1 |
| METHOD FOR CORRECTING COGNITIVE IMPAIRMENT IN PATIENTS DURING THE PERIOD OF CONVALESCENCE OF CORONAVIRUS INFECTION CASED BY THE SARS-CoV-2 VIRUS | 2022 |
|
RU2801379C1 |
| METHOD OF PREDICTING THE RISK OF DEATH FROM COVID-19 IN YOUNG PATIENTS | 2023 |
|
RU2803002C1 |
| METHOD FOR PREDICTING RISK OF DEATH AT HOSPITAL STAGE IN PATIENTS WITHOUT ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION WHO HAVE UNDERGONE NEW COVID-19 CORONAVIRUS INFECTION, TAKING INTO ACCOUNT THEIR IMMUNOLOGICAL STATUS | 2022 |
|
RU2781565C1 |
| METHOD FOR DETERMINING THE RISK OF DEVELOPING ACUTE MYOCARDIAL INFARCTION IN PATIENTS WITH ESSENTIAL ARTERIAL HYPERTENSION FOR 18 MONTHS AFTER A NEW CORONAVIRUS INFECTION (COVID-19) | 2024 |
|
RU2835912C1 |
| METHOD FOR ASSESSING THE RISK OF DEVELOPING A SEVERE COURSE OF CoVID-19 | 2022 |
|
RU2782796C1 |
| METHOD FOR PREDICTING THE RISK OF DEATH WITHIN 6 MONTHS AFTER SUFFERING A NEW CORONAVIRUS INFECTION COVID-19 | 2021 |
|
RU2766302C1 |
| METHOD FOR DETERMINING RISK OF DEVELOPING ACUTE CEREBROVASCULAR ACCIDENT IN PATIENTS WITH ESSENTIAL ARTERIAL HYPERTENSION FOR 12 MONTHS AFTER COVID-19 | 2023 |
|
RU2826593C1 |
| METHOD FOR PREDICTING THE RISK OF DEVELOPING LEFT VENTRICULAR GLOBAL LONGITUDINAL DEFORMITY AFTER COVID-19 PNEUMONIA IN INDIVIDUALS WITHOUT PULMONARY EMBOLISM, PERIPHERAL THROMBOSIS, CORONARY HEART DISEASE, AND ATRIAL FIBRILLATION | 2022 |
|
RU2782299C1 |
| METHOD FOR EARLY DETECTION OF NEUROLOGICAL DISORDERS IN PATIENTS WITH COVID-19 | 2021 |
|
RU2779562C1 |
